Compare Keysight Technologies Inc (KEYS) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs Pfizer Inc — how do they compare? Keysight Technologies Inc trades at $381.74 (market cap $63.79B), while Pfizer Inc trades at $28.2 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 2.5× Keysight Technologies Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Keysight Technologies Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Keysight Technologies Inc for 56 Days and Pfizer Inc for 158 Days on average.
| KEYS | PFE | |
|---|---|---|
Market Cap | $63.79B | $158.56B |
Volume | 1,435,384 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $387.90 | $29.02 |
52-Week Low | $159.49 | $23.67 |
Typical Hold Time | 56 Days | 158 Days |
Enterprise Value | $63.93B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $382.75, up 0.33% with strong technical momentum as it approaches resistance at $385. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $3.07 versus $2.48, supported by 19.14% net margins and 20.59% ROE. Recent news highlights AI infrastructure demand and 6G development opportunities, with orders surging 56% in Q3 2026.
Wall Street maintains strong bullish sentiment with 81% buy ratings and $416.63 consensus target, though elevated P/E of 50.7 presents valuation risk. Growth catalysts include AI data-center expansion and 6G wireless development, while risks involve supply constraints and competitive pressures in the testing equipment market.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
